🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📆Join Dr Patrick Hanley at our next Advanced Therapies Seminar where he will discuss T cell therapy and its use in viral infections and malignancies. Further information can be found here: newcastlehealthinnovation.org/events/nhip-ad…

I know we like to quote the cost of drugs based on when they’re first approved but drugs are not immune to inflation. That $373,000 or $475,000 price from 2017 is not accurate in 2024. ⬆️ $50-100k. Time to update your slides.

1/ This is the next chapter of a story about courageous patients and their families, of multidisciplinary teamwork, and hard-fought steps forward to effective therapy for #DIPG #DMG, a universally lethal cancer of the brain and spinal cord. 🧵nature.com/articles/s4158…

IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer). nature.com/articles/s4158…

They finally did it! Mesoblast News’s Ryoncil approved for steroid refractory GVHD post stem cell transplant. How well will it be adopted given how much transplant has changed since MSCs first showed potential benefit many years ago? fda.gov/news-events/pr…

The co-founders of the Stem Cell Institute of America and related companies have been banned from offering stem cell therapy and ordered to pay $5 million to consumers who were tricked into buying their unproven therapy consumeraffairs.com/news/stem-cell…

Find me a better tradition than #BillsMafia donating significant $$$ to charities in honor of their own or opposing players like Mark Andrews 8⃣9️⃣ Lamar Jackson, Andy Dalton. And of course Josh Allen, 𝐃𝐚𝐦𝐚𝐫 𝐇𝐚𝐦𝐥𝐢𝐧. thebaltimorebanner.com/sports/ravens-…

Off-the-shelf CAR-T is here! Our phase 1 trial in Journal of Clinical Oncology shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL: 🔹42% CR rate with median CR duration 23.1 months 🔹No GVHD, ICANS, or severe CRS ascopubs.org/doi/10.1200/JC…

Today bluebird bio announced a definitive agreement to be acquired by Carlyle and SK Capital. Read more in our press release: investor.bluebirdbio.com/news-releases/…

.bluebird bio acq by SK and Carlyle. W/ 3 drugs (Skysona, Lyfgenia, and Zynteglo) will be interesting to see if this is enough to make these gene therapies a commercial success. FDA’s decision not to award a priority review voucher may have played a role businesswire.com/news/home/2025…

Summary Report from the 21st #FDA Cell Therapy Liaison Meeting published by ISCT isctglobal.org/publications/r…

I'm deeply honored to receive the ISCT Career Achievement Award. This recognition reflects the efforts of many in the Center for Cellular Immunotherapies directed by Carl June, and collaborators Penn Medicine & Children's Hospital. I'm grateful to ISCT for decades of support,

Sad to see that Dr Marks of U.S. FDA’s CBER branch has resigned. A true champion of cell and gene therapies reuters.com/business/healt…

Excited to share a publication years in the making, our experience with CAR20.19 T cells in relapsed, refractory Mantle Cell Lymphoma now a. Excellent outcomes from IIT MCW Cancer Center Thanks to great collaborators Tim Fenske Mehdi Hamadani, MD and many more! ascopubs.org/doi/10.1200/JC…

dyk the Human Genome Project cost taxpayers about $ 3 Billion over 13 years but is estimated to have a generated an ROI of $1 Trillion impacting the fields of medicine, agriculture, energy, and the environment. Science is not a cost. It’s an investment with countless returns.

Ever wanted to hear a CART cell song from an award winning musician who has sang at the White House… with lyrics from Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 ? Here it is! 👏👏👏